| Outcome Measures: |
Primary: Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP, \*Hypoglycemia, urinary tract infection, genital infection, pollakiuria, or polyuria, at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP | Secondary: Changes from baseline* in HbA1c at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP, \* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001301), at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP|Changes from baseline* in FPG at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP, \* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001301), at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP|Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP, \* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001301), at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
|
